{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:17:33Z","timestamp":1767140253668,"version":"build-2238731810"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-023-01208-9","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T11:02:19Z","timestamp":1697194939000},"page":"4237-4248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia"],"prefix":"10.1007","volume":"23","author":[{"given":"Xiangxing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaojiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenwei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suping","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"issue":"25","key":"1208_CR1","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360. https:\/\/doi.org\/10.1182\/blood-2017-09-806398.","journal-title":"Blood"},{"issue":"21","key":"1208_CR2","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","volume":"131","author":"IE Ahn","year":"2018","unstructured":"Ahn IE, Farooqui M, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131(21):2357\u201366. https:\/\/doi.org\/10.1182\/blood-2017-12-820910.","journal-title":"Blood"},{"issue":"9747","key":"1208_CR3","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(10)61381-5.","journal-title":"Lancet"},{"issue":"1","key":"1208_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"SS Pal","year":"2018","unstructured":"Pal SS, Dammeijer F, Hendriks RW. Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57. https:\/\/doi.org\/10.1186\/s12943-018-0779-z.","journal-title":"Mol Cancer"},{"key":"1208_CR5","doi-asserted-by":"publisher","unstructured":"Garg N, Padron EJ, Rammohan KW, et al. Bruton's Tyrosine Kinase Inhibitors: the next frontier of b-cell-targeted therapies for cancer, autoimmune disorders, and multiple sclerosis. J Clin Med. 2022;11(20). https:\/\/doi.org\/10.3390\/jcm11206139","DOI":"10.3390\/jcm11206139"},{"issue":"9","key":"1208_CR6","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1007\/s12325-022-02238-7","volume":"39","author":"W Xu","year":"2022","unstructured":"Xu W, Yang S, Tam CS, et al. Zanubrutinib monotherapy for Na\u00efve and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: a pooled analysis of three studies. Adv Ther. 2022;39(9):4250\u201365. https:\/\/doi.org\/10.1007\/s12325-022-02238-7.","journal-title":"Adv Ther"},{"issue":"4","key":"1208_CR7","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/bjh.17984","volume":"196","author":"JN Allan","year":"2022","unstructured":"Allan JN, Shanafelt T, Wiestner A, et al. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Br J Haematol. 2022;196(4):947\u201353. https:\/\/doi.org\/10.1111\/bjh.17984.","journal-title":"Br J Haematol"},{"issue":"4","key":"1208_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/bjh.15421","volume":"182","author":"J Jones","year":"2018","unstructured":"Jones J, Mato A, Coutre S, et al. Evaluation of 230 patients with relapsed\/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. Br J Haematol. 2018;182(4):504\u201312. https:\/\/doi.org\/10.1111\/bjh.15421.","journal-title":"Br J Haematol"},{"issue":"15","key":"1208_CR9","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","volume":"26","author":"JC Byrd","year":"2020","unstructured":"Byrd JC, Furman RR, Coutre SE, et al. Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study. Clin Cancer Res. 2020;26(15):3918\u201327. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2856.","journal-title":"Clin Cancer Res"},{"key":"1208_CR10","doi-asserted-by":"publisher","unstructured":"Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial Lancet, 2020;395(10232):1278\u201391. https:\/\/doi.org\/10.1016\/S0140-6736(20)30262-2","DOI":"10.1016\/S0140-6736(20)30262-2"},{"issue":"Suppl 2","key":"1208_CR11","doi-asserted-by":"publisher","first-page":"S269","DOI":"10.1016\/S2152-2650(22)01329-5","volume":"22","author":"BS Kahl","year":"2022","unstructured":"Kahl BS, Giannopoulos K, Jurczak W, et al. CLL-137 SEQUOIA: results of a phase 3 randomized study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in patients with treatment-Na\u00efve (TN) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/ SLL). Clin Lymphoma Myeloma Leuk. 2022;22(Suppl 2):S269\u201370.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"1208_CR12","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3026(20)30433-6","volume":"8","author":"JP Sharman","year":"2021","unstructured":"Sharman JP, Brander DM, Mato AR, et al. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet Haematol. 2021;8(4):e254\u201366. https:\/\/doi.org\/10.1016\/S2352-3026(20)30433-6.","journal-title":"Lancet Haematol"},{"issue":"10","key":"1208_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","volume":"133","author":"JA Burger","year":"2019","unstructured":"Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133(10):1011\u20139. https:\/\/doi.org\/10.1182\/blood-2018-10-879429.","journal-title":"Blood"},{"issue":"5","key":"1208_CR14","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1200\/JCO.22.00510","volume":"41","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Eichhorst B, Brown JR, et al. Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncol. 2023;41(5):1035\u201345. https:\/\/doi.org\/10.1200\/JCO.22.00510.","journal-title":"J Clin Oncol"},{"key":"1208_CR15","doi-asserted-by":"publisher","unstructured":"Morche J, Freitag S, Hoffmann F, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. Z Evid Fortbild Qual Gesundhwes, 2020,150\u2013152:124\u2013133. https:\/\/doi.org\/10.1016\/j.zefq.2019.11.003","DOI":"10.1016\/j.zefq.2019.11.003"},{"issue":"5","key":"1208_CR16","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/bjh.17994","volume":"196","author":"G Cull","year":"2022","unstructured":"Cull G, Burger JA, Opat S, et al. Zanubrutinib for treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I\/II AU-003 study. Br J Haematol. 2022;196(5):1209\u201318. https:\/\/doi.org\/10.1111\/bjh.17994.","journal-title":"Br J Haematol"},{"issue":"25","key":"1208_CR17","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1509388.","journal-title":"N Engl J Med"},{"issue":"26","key":"1208_CR18","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1812836.","journal-title":"N Engl J Med"},{"issue":"31","key":"1208_CR19","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441\u201352. https:\/\/doi.org\/10.1200\/JCO.21.01210.","journal-title":"J Clin Oncol"},{"key":"1208_CR20","doi-asserted-by":"publisher","unstructured":"Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or Ibrutinib in relapsed or refractory chronic lymphocytic leukemia[J]. N Engl J Med. 2023;388(4):319\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2211582","DOI":"10.1056\/NEJMoa2211582"},{"issue":"12","key":"1208_CR21","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1158\/1078-0432.CCR-19-3504","volume":"26","author":"AV Danilov","year":"2020","unstructured":"Danilov AV, Herbaux C, Walter HS, et al. Phase Ib study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2020;26(12):2810\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3504.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1208_CR22","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.clinthera.2020.08.017","volume":"42","author":"MS Davids","year":"2020","unstructured":"Davids MS, Waweru C, Le Nouveau P, et al. Comparative efficacy of acalabrutinib in frontline treatment of chronic lymphocytic leukemia: a systematic review and network meta-analysis. Clin Ther. 2020;42(10):1955\u201374. https:\/\/doi.org\/10.1016\/j.clinthera.2020.08.017.","journal-title":"Clin Ther"},{"key":"1208_CR23","doi-asserted-by":"publisher","unstructured":"Chen P H, Ho C L, Lin C, et al. Treatment outcomes of novel targeted agents in relapse\/refractory chronic lymphocytic leukemia: a systematic review and network meta-analysis. J Clin Med, 2019,8(5). https:\/\/doi.org\/10.3390\/jcm8050737","DOI":"10.3390\/jcm8050737"}],"updated-by":[{"DOI":"10.1007\/s10238-023-01251-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000}}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01208-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01208-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01208-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T11:23:02Z","timestamp":1702725782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01208-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1208"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01208-9","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10238-023-01251-6","URL":"https:\/\/doi.org\/10.1007\/s10238-023-01251-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We declare that we have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. All authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}